non-Hodgkin lymphoma

Summary

non-Hodgkin lymphoma (MONDO:0018908) is a cancer (an umbrella term covering 10 Mondo subtypes) with 8 cohort genes (92 GWAS associations across 31 studies; 5 CIViC-evidence somatic drivers; 13 ClinVar predisposition records) and 1,051 clinical trials. Molecularly, EZH2 Y646F confers sensitivity to Tazemetostat in Non-Hodgkin Lymphoma (CIViC Level D). Top therapeutic interventions include rituximab, bendamustine, and plerixafor.

At a glance

• Classification: Cancer
• Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
• Umbrella term: 10 Mondo subtypes
• Cohort genes: 8
• GWAS associations: 92
• ClinVar variants: 13
• Clinical trials: 1,051
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-5 / 10 000	11.6	Europe	Validated
Point prevalence	1-5 / 10 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	non-Hodgkin lymphoma
Mondo ID	MONDO:0018908
EFO	EFO:0005952
MeSH	D008228
Orphanet	547
DOID	DOID:0060060
NCIT	C3211
UMLS	C0024305
MedGen	6160
MedDRA	10029547
Is cancer (heuristic)	yes

Also known as: NHL · non-Hodgkin lymphoma · non-Hodgkin’s lymphoma · non-Hodgkin’s lymphoma (NHL) · non-Hodgkins lymphoma

Data availability: 13 ClinVar variants · 92 GWAS associations (31 studies) · 14 cell lines · 55 intOGen driver records.

Disease family

An umbrella term covering 10 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › non-Hodgkin lymphoma

Related subtypes (26): prostate lymphoma, nasal cavity lymphoma, bladder lymphoma, tracheal lymphoma, retroperitoneal lymphoma, ureteral lymphoma, ovarian lymphoma, B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, pediatric lymphoma, adult lymphoma, breast lymphoma, heart lymphoma, chest wall lymphoma, lung lymphoma, mediastinal malignant lymphoma, eye lymphoma, B-cell neoplasm, gastrointestinal lymphoma, Hodgkins lymphoma, peripheral T-cell lymphoma, not otherwise specified, composite lymphoma, AIDS-related primary central nervous system lymphoma, primary organ-specific lymphoma, extranodal nasal NK/T cell lymphoma, methotrexate-associated lymphoproliferative disorders, progressive transformation of germinal centers

Subtypes (10): lymphoblastic lymphoma, lymphosarcoma, acute lymphoblastic leukemia, lymphoma, non-Hodgkin, familial, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, lung non-Hodgkin lymphoma, ocular adnexal lymphoma, large-cell immunoblastic lymphoma, gastric non-hodgkin lymphoma

Genetics & variants

GWAS landscape

92 GWAS associations across 31 studies. Top hits map to 33 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs12682374	9e-29	PCAT1, CASC8, POU5F1B	?	0.93
rs1219651	1e-25	FGFR2	?	1.09
rs2981584	1e-21	FGFR2	?	0.94
rs10908278	3e-21	HNF1B	?	1.06
rs2097442	1e-19	HLA-DRA - HLA-DRB9	?	1.36
rs4538746	2e-17	HLA-DQB1	T	1.22
rs112149573	2e-17	TOX3	?	1.08
rs78540526	1e-15	LINC01488 - PNCRNA-D	?	1.13
rs35409710	2e-15	HLA-DQB1	?	1.09
rs7463708	2e-15	PCAT1, PRNCR1, CASC19	?	1.08
rs2858314	6e-15	HLA-DQB1 - MTCO3P1	G	0.16
rs34102154	1e-14	HLA-DRB1 - HLA-DQA1	G	1.43
rs11651755	1e-14	HNF1B	?	1.06
rs1485995	8e-14	LINC01488	?	0.95
rs9273736	2e-13	HLA-DQB1	?	1.12
rs2976384	3e-13	PSCA, JRK	?	1.07
rs3806624	5e-13	EOMES - LINC01980	G	1.14
rs35923643	8e-13	GRAMD1B	G	1.19
rs17676949	2e-12	PHLPP1 - BCL2	A	0.78
rs2585181	3e-12	PSCA - LY6K	?	1.05
rs2471960	1e-11	UQCRHP1 - AIF1	A	1.23
rs3789068	1e-11	MIR4435-2HG, BCL2L11	G	1.13
rs13255292	1e-11	PVT1	C	0.13
rs12365699	2e-11	Y_RNA - CXCR5	G	0.16
rs2765974	2e-11	CELF2	C	0.13
rs149482608	2e-11	SNHG10	A	1.67
rs150480567	2e-11	MTCO3P1 - HLA-DQB3	?	0.17
rs183161500	3e-11	LINC01523	A	3.03
rs7919208	5e-11	LINC00841 - LINC03089	?	1.23
rs4007642	6e-11	CDKN2B-AS1	?	0.96

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90651054	Sato G	2023	43,098	334,343	Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis.
GCST90308764	Sato G	2023	29,753	150,462	Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis.
GCST90651069	Sato G	2023	29,753	150,462	Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis.
GCST90267403	Berndt SI	2022	13,763	18,862	Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
GCST90477247	Verma A	2024	5,910	443,358	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90011819	Rashkin SR	2020	2,400	410,350	Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts.
GCST90651049	Sato G	2023	1,997	334,343	Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis.
GCST90435644	Zhou W	2018	1,793	404,466	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90079638	Backman JD	2021	1,579	386,126	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083624	Backman JD	2021	1,579	386,126	Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	5
Tier 4: intronic/intergenic	45

MAF distribution

Bucket	Variants
common (>=0.05)	45
low_freq (0.01-0.05)	0
rare (<0.01)	2
unknown	3

Functional consequences

Consequence	Count
intron_variant	28
intergenic_variant	14
regulatory_region_variant	5
non_coding_transcript_exon_variant	3

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs12682374	8	127398703	C>A,G,T	0.05	intron_variant	PCAT1, CASC8, POU5F1B	9e-29	Tier 4: intronic/intergenic
rs1219651	10	121584987	G>A,C,T	0.05	intron_variant	FGFR2	1e-25	Tier 4: intronic/intergenic
rs2981584	10	121590702	A>C,G,T	0.05	intron_variant	FGFR2	1e-21	Tier 4: intronic/intergenic
rs10908278	17	37739961	A>C,G,T	0.05	intron_variant	HNF1B	3e-21	Tier 4: intronic/intergenic
rs2097442	6	32454414	G>A,T	0.05	intron_variant	HLA-DRA - HLA-DRB9	1e-19	Tier 4: intronic/intergenic
rs4538746	6	32664336	C>A,G,T	0.05	intron_variant	HLA-DQB1	2e-17	Tier 4: intronic/intergenic
rs112149573	16	52547333	G>C,T	0.05	intron_variant	TOX3	2e-17	Tier 4: intronic/intergenic
rs78540526	11	69516650	C>T	0.05	regulatory_region_variant	LINC01488 - PNCRNA-D	1e-15	Tier 3: regulatory
rs35409710	6	32661126	G>A	0.05	intron_variant	HLA-DQB1	2e-15	Tier 4: intronic/intergenic
rs7463708	8	127091810	G>A,C,T	0.05	non_coding_transcript_exon_variant	PCAT1, PRNCR1, CASC19	2e-15	Tier 4: intronic/intergenic
rs2858314	6	32695671	G>A,C	0.233	intergenic_variant	HLA-DQB1 - MTCO3P1	6e-15	Tier 4: intronic/intergenic
rs34102154	6	32604329	G>A	0.05	regulatory_region_variant	HLA-DRB1 - HLA-DQA1	1e-14	Tier 3: regulatory
rs11651755	17	37739849	T>C	0.05	intron_variant	HNF1B	1e-14	Tier 4: intronic/intergenic
rs1485995	11	69492939	G>A,C	0.05	non_coding_transcript_exon_variant	LINC01488	8e-14	Tier 4: intronic/intergenic
rs9273736	6	32661595	G>A,C	0.05	intron_variant	HLA-DQB1	2e-13	Tier 4: intronic/intergenic
rs2976384	8	142671576	T>A,C	0.05	intergenic_variant	PSCA, JRK	3e-13	Tier 4: intronic/intergenic
rs3806624	3	27723132	A>C,G,T	0.05	regulatory_region_variant	EOMES - LINC01980	5e-13	Tier 3: regulatory
rs35923643	11	123484683	A>G	0.05	intron_variant	GRAMD1B	8e-13	Tier 4: intronic/intergenic
rs17676949	18	63118405	G>A,C	0.05	intergenic_variant	PHLPP1 - BCL2	2e-12	Tier 4: intronic/intergenic
rs2585181	8	142690296	C>A	0.05	intergenic_variant	PSCA - LY6K	3e-12	Tier 4: intronic/intergenic
rs2471960	6	31612762	G>A,T	0.05	intron_variant	UQCRHP1 - AIF1	1e-11	Tier 4: intronic/intergenic
rs3789068	2	111151670	A>G	0.05	intron_variant	MIR4435-2HG, BCL2L11	1e-11	Tier 4: intronic/intergenic
rs13255292	8	128064327	C>T	0.267	intron_variant	PVT1	1e-11	Tier 4: intronic/intergenic
rs12365699	11	118872577	G>A	0.137	regulatory_region_variant	Y_RNA - CXCR5	2e-11	Tier 3: regulatory
rs2765974	10	11246455	C>A,G,T	0.389	intron_variant	CELF2	2e-11	Tier 4: intronic/intergenic
rs149482608	14	95525224	A>G	0.001	intron_variant	SNHG10	2e-11	Tier 4: intronic/intergenic
rs150480567	6	32712473			intergenic_variant	MTCO3P1 - HLA-DQB3	2e-11	Tier 4: intronic/intergenic
rs183161500	20	48008648	A>C,G	0	intron_variant	LINC01523	3e-11	Tier 4: intronic/intergenic
rs7919208	10	44178109	G>A,T	0.05	intergenic_variant	LINC00841 - LINC03089	5e-11	Tier 4: intronic/intergenic
rs4007642	9	22093300	A>C,T	0.05	intron_variant	CDKN2B-AS1	6e-11	Tier 4: intronic/intergenic

ClinVar germline variants

13 retrieved; paginated sample, class counts are floors:

6 pathogenic, 3 conflicting classifications of pathogenicity, 1 pathogenic/likely pathogenic, 1 benign, 1 likely benign, 1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
31907	NM_004048.4(B2M):c.286G>A (p.Asp96Asn)	B2M	Pathogenic	criteria provided, single submitter
13970	NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)	BRAF	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
13971	NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala)	BRAF	Pathogenic	criteria provided, single submitter
7765	NM_032977.4(CASP10):c.1241C>T (p.Ala414Val)	CASP10	Pathogenic	no assertion criteria provided
7766	NM_032977.4(CASP10):c.769C>T (p.Gln257Ter)	CASP10	Pathogenic	no assertion criteria provided
7767	NM_032977.4(CASP10):c.1042_1043insA (p.Gly348fs)	CASP10	Pathogenic	no assertion criteria provided
6192	NM_003579.4(RAD54L):c.1331T>A (p.Val444Glu)	RAD54L	Pathogenic	no assertion criteria provided
13972	NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)	BRAF	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
801487	NM_003579.4(RAD54L):c.796G>C (p.Val266Leu)	RAD54L	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
12367	NM_000546.6(TP53):c.974G>T (p.Gly325Val)	TP53	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
801489	NM_003579.4(RAD54L):c.1870-1G>A	LRRC41	Uncertain significance	criteria provided, single submitter
5638	NM_012415.3(RAD54B):c.1778A>G (p.Asn593Ser)	RAD54B	Benign	criteria provided, single submitter
801488	NM_003579.4(RAD54L):c.888C>T (p.Asp296=)	RAD54L	Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 36 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
EZH2	Act	ALL,AML,DLBCLNOS,ES,MLYM,NHL	CIViC #63
BRAF	Act	BLCA,BRCA,CHOL,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,GBM,GIST,HGGNOS,LGGNOS,LUAD,MEL,MLYM,NSCLC,OVT,PAST,PCM,PRAD,PRCC,PROSTATE,READ,SACA,SKCM,STAD,UCEC,WDTC	CIViC #5
TP53	LoF	ACC,ALL,AML,ANGS,ANSC,BCC,BL,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,EGC,ES,ESCA,ESCC,GB,GBC,GBM,GIST,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LNM,LUAD,LUSC,MBL,MEL,MLYM,MT,NBL,NETNOS,NHL,NPC,NSCLC,OS,OVT,PAAD,PANCREAS,PAST,PCM,PLMESO,PRAD,PRCC,PROSTATE,RCC,READ,SACA,SARCNOS,SCLC,SIC,SKCM,SKIN,SOFT_TISSUE,STAD,STOMACH,THYM,UCEC,UCS,UTUC,VULVA,WDTC,WT	CIViC #45
B2M	LoF	CESC,DLBCLNOS,HNSC,MEL,MLYM,NHL,NSCLC	CIViC #537
RAD54L			CIViC #6676

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
EZH2	Orphanet:3447	Weaver syndrome
BRAF	Orphanet:1340	Cardiofaciocutaneous syndrome
BRAF	Orphanet:146	Differentiated thyroid carcinoma
BRAF	Orphanet:251615	Pilomyxoid astrocytoma
BRAF	Orphanet:389	Langerhans cell histiocytosis
BRAF	Orphanet:500	Noonan syndrome with multiple lentigines
BRAF	Orphanet:54595	Craniopharyngioma
BRAF	Orphanet:58017	Classic hairy cell leukemia
BRAF	Orphanet:626	Large/giant congenital melanocytic nevus
BRAF	Orphanet:648	Noonan syndrome
BRAF	Orphanet:840	Syringocystadenoma papilliferum
BRAF	Orphanet:96253	Cushing disease
TP53	Orphanet:1333	Familial pancreatic carcinoma
TP53	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
TP53	Orphanet:1501	Adrenocortical carcinoma
TP53	Orphanet:210159	Adult hepatocellular carcinoma
TP53	Orphanet:251576	Gliosarcoma
TP53	Orphanet:251579	Giant cell glioblastoma
TP53	Orphanet:251899	Choroid plexus carcinoma
TP53	Orphanet:2807	Papilloma of choroid plexus
TP53	Orphanet:293199	Pleomorphic rhabdomyosarcoma
TP53	Orphanet:3318	Essential thrombocythemia
TP53	Orphanet:524	Li-Fraumeni syndrome
TP53	Orphanet:52688	Myelodysplastic syndrome
TP53	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
TP53	Orphanet:668	Osteosarcoma
TP53	Orphanet:67038	B-cell chronic lymphocytic leukemia
TP53	Orphanet:70573	Small cell lung cancer
TP53	Orphanet:96253	Cushing disease
TP53	Orphanet:99756	Alveolar rhabdomyosarcoma
TP53	Orphanet:99757	Embryonal rhabdomyosarcoma
CASP10	Orphanet:3261	Autoimmune lymphoproliferative syndrome
B2M	Orphanet:314652	Variant ABeta2M amyloidosis
B2M	Orphanet:34592	Immunodeficiency by defective expression of MHC class I
RAD54L	Orphanet:227535	Hereditary breast cancer

Cohort genes → proteins

8 cohort genes, 8 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1
multi_evidence	7

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
EZH2	HGNC:3527	ENSG00000106462	Q15910	Histone-lysine N-methyltransferase EZH2	civic_evidence
BRAF	HGNC:1097	ENSG00000157764	P15056	Serine/threonine-protein kinase B-raf	clinvar
TP53	HGNC:11998	ENSG00000141510	P04637	Cellular tumor antigen p53	clinvar
CASP10	HGNC:1500	ENSG00000003400	Q92851	Caspase-10	clinvar
LRRC41	HGNC:16917	ENSG00000132128	Q15345	Leucine-rich repeat-containing protein 41	clinvar
RAD54B	HGNC:17228	ENSG00000197275	Q9Y620	DNA repair and recombination protein RAD54B	clinvar
B2M	HGNC:914	ENSG00000166710	P61769	Beta-2-microglobulin	clinvar
RAD54L	HGNC:9826	ENSG00000085999	Q92698	DNA repair and recombination protein RAD54-like	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
EZH2	Histone-lysine N-methyltransferase EZH2	Catalytic subunit of the PRC2/EED-EZH2 complex, a Polycomb group (PcG) complex that methylates ‘Lys-9’ (H3K9me) and ‘Lys-27’ (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene.
BRAF	Serine/threonine-protein kinase B-raf	Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus.
TP53	Cellular tumor antigen p53	Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.
CASP10	Caspase-10	Involved in the activation cascade of caspases responsible for apoptosis execution.
LRRC41	Leucine-rich repeat-containing protein 41	Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.
RAD54B	DNA repair and recombination protein RAD54B	Multifunctional ATPase that could play with RAD54, a redundant role in homologous recombination (HR), a major pathway for repairing DNA double-strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or collapsed replication for…
B2M	Beta-2-microglobulin	Component of the class I major histocompatibility complex (MHC).
RAD54L	DNA repair and recombination protein RAD54-like	Multifunctional ATPase that plays a role in homologous recombination (HR) which is a major pathway for repairing DNA double-strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or collapsed replication forks.

Protein-family classification

Druggable: 6 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.75

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	4	6.0×	0.013
Antibody/Immunoglobulin	1	3.6×	0.424
Kinase	1	3.5×	0.424
Transcription factor	1	1.0×	0.805
Other/Unknown	1	0.2×	0.999

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
EZH2	Enzyme (other)	yes	2.1.1.356	SANT/Myb, SET_dom, EZH1/EZH2_N
BRAF	Kinase	yes	2.7.10.2	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, PKC_DAG/PE
TP53	Transcription factor	no		p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn
CASP10	Enzyme (other)	yes	3.4.22.63	Pept_C14_p20, DED_dom, Pept_C14_p10
LRRC41	Other/Unknown	no		Leu_rpt_41, LRR_dom_sf
RAD54B	Enzyme (other)	yes	3.6.4.B9	SNF2_N, Helicase_C-like, Helicase_ATP-bd
B2M	Antibody/Immunoglobulin	yes		Ig/MHC_CS, Ig_C1-set, Ig-like_dom
RAD54L	Enzyme (other)	yes	3.6.4.B9	SNF2_N, Helicase_C-like, Helicase_ATP-bd

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	8
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ventricular zone	3
ganglionic eminence	2
colonic epithelium	2
granulocyte	2
monocyte	2
right uterine tube	2
embryo	1
buccal mucosa cell	1
calcaneal tendon	1
tendon of biceps brachii	1
adenohypophysis	1
left uterine tube	1
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1
leukocyte	1
left testis	1
right testis	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
EZH2	216	ubiquitous	marker	ganglionic eminence, ventricular zone, embryo
BRAF	265	ubiquitous	marker	buccal mucosa cell, colonic epithelium, calcaneal tendon
TP53	223	ubiquitous	marker	ventricular zone, ganglionic eminence, tendon of biceps brachii
CASP10	206	ubiquitous	marker	colonic epithelium, granulocyte, monocyte
LRRC41	281	ubiquitous	marker	right uterine tube, left uterine tube, adenohypophysis
RAD54B	201	ubiquitous	yes	right uterine tube, primordial germ cell in gonad, male germ line stem cell (sensu Vertebrata) in testis
B2M	134	ubiquitous	marker	granulocyte, monocyte, leukocyte
RAD54L	173	ubiquitous	yes	left testis, right testis, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TP53	22,736
EZH2	9,646
BRAF	7,394
RAD54L	2,927
RAD54B	2,743
CASP10	1,242
LRRC41	683
B2M	415

Intra-cohort edges

A	B	Sources
BRAF	TP53	string_interaction
CASP10	TP53	string_interaction

Structural data

PDB: 6 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
B2M	P61769	1,226
TP53	P04637	313
BRAF	P15056	131
EZH2	Q15910	38
RAD54B	Q9Y620	4
RAD54L	Q92698	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
LRRC41	Q15345	71.96
CASP10	Q92851	69.54

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 139. Enrichment computed across 8 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
TP53 Regulates Transcription of Caspase Activators and Caspases	2	317.2×	0.002	TP53, CASP10
Loss of function of TP53 in cancer due to loss of tetramerization ability	1	1903.3×	0.024	TP53
Regulation of PTEN gene transcription	2	59.5×	0.024	TP53, EZH2
Regulation of TP53 Expression	1	951.7×	0.029	TP53
Transcriptional activation of cell cycle inhibitor p21	1	475.8×	0.029	TP53
Signaling by MRAS-complex mutants	1	475.8×	0.029	BRAF
Signalling to p38 via RIT and RIN	1	380.7×	0.029	BRAF
FasL/ CD95L signaling	1	380.7×	0.029	CASP10
Activation of NOXA and translocation to mitochondria	1	317.2×	0.029	TP53
Negative feedback regulation of MAPK pathway	1	317.2×	0.029	BRAF
ARMS-mediated activation	1	271.9×	0.029	BRAF
RUNX3 regulates CDKN1A transcription	1	271.9×	0.029	TP53
Modulation by Mtb of host immune system	1	271.9×	0.029	B2M
Prolonged ERK activation events	1	237.9×	0.029	BRAF
TRAIL signaling	1	237.9×	0.029	CASP10
SHOC2 M1731 mutant abolishes MRAS complex function	1	237.9×	0.029	BRAF
Gain-of-function MRAS complexes activate RAF signaling	1	237.9×	0.029	BRAF
PI5P Regulates TP53 Acetylation	1	211.5×	0.029	TP53
Activation of PUMA and translocation to mitochondria	1	190.3×	0.029	TP53
Nef mediated downregulation of MHC class I complex cell surface expression	1	190.3×	0.029	B2M
Signaling by FGFR3	1	190.3×	0.029	BRAF
Infection with Mycobacterium tuberculosis	1	190.3×	0.029	B2M
RHOBTB3 ATPase cycle	1	190.3×	0.029	LRRC41
Oxidative Stress Induced Senescence	2	30.2×	0.029	TP53, EZH2
Class I MHC mediated antigen processing & presentation	2	23.4×	0.029	LRRC41, B2M
Endosomal/Vacuolar pathway	1	173.0×	0.030	B2M
Signaling by FGFR4	1	173.0×	0.030	BRAF
Frs2-mediated activation	1	158.6×	0.030	BRAF
TP53 Regulates Transcription of Death Receptors and Ligands	1	158.6×	0.030	TP53
Urea cycle	1	146.4×	0.030	TP53

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 8 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
determination of adult lifespan	3	162.0×	9e-05	TP53, RAD54B, RAD54L
T cell differentiation in thymus	3	154.1×	9e-05	BRAF, TP53, B2M
positive regulation of cellular senescence	2	324.1×	0.001	TP53, B2M
positive regulation of execution phase of apoptosis	2	210.7×	0.002	TP53, CASP10
chromosome organization	2	145.3×	0.003	TP53, RAD54L
reciprocal meiotic recombination	2	140.4×	0.003	RAD54B, RAD54L
response to ionizing radiation	2	102.8×	0.006	RAD54B, RAD54L
negative regulation of iron ion transport	1	2106.5×	0.008	B2M
negative regulation of helicase activity	1	2106.5×	0.008	TP53
cellular response to actinomycin D	1	2106.5×	0.008	TP53
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	1	2106.5×	0.008	TP53
negative regulation of G1 to G0 transition	1	2106.5×	0.008	TP53
positive regulation of neuron apoptotic process	2	68.0×	0.008	TP53, CASP10
cellular response to xenobiotic stimulus	2	60.2×	0.008	BRAF, TP53
antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent	1	1053.2×	0.010	B2M
regulation of iron ion transport	1	1053.2×	0.010	B2M
positive regulation of mitochondrial membrane permeability	1	1053.2×	0.010	TP53
hepatocyte homeostasis	1	1053.2×	0.010	EZH2
cellular response to iron(III) ion	1	1053.2×	0.010	B2M
oligodendrocyte apoptotic process	1	1053.2×	0.010	TP53
negative regulation of glucose catabolic process to lactate via pyruvate	1	1053.2×	0.010	TP53
negative regulation of pentose-phosphate shunt	1	1053.2×	0.010	TP53
negative regulation of forebrain neuron differentiation	1	1053.2×	0.010	B2M
regulation of gliogenesis	1	702.2×	0.011	EZH2
obsolete homolactic fermentation	1	702.2×	0.011	TP53
cellular response to trichostatin A	1	702.2×	0.011	EZH2
CD4-positive or CD8-positive, alpha-beta T cell lineage commitment	1	702.2×	0.011	BRAF
signal transduction by p53 class mediator	1	702.2×	0.011	TP53
negative regulation of miRNA processing	1	702.2×	0.011	TP53
intrinsic apoptotic signaling pathway in response to hypoxia	1	702.2×	0.011	TP53

Therapeutics

Drugs indicated for this disease

6 approved, 51 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Brentuximab Vedotin	Approved (phase 4)
Carmustine	Approved (phase 4)
Idelalisib	Approved (phase 4)
Methotrexate	Approved (phase 4)
Plerixafor	Approved (phase 4)
Rituximab	Approved (phase 4)
Allopurinol	Phase 3 (in late-stage trials)
Amoxicillin	Phase 3 (in late-stage trials)
Asparaginase	Phase 3 (in late-stage trials)
Bendamustine	Phase 3 (in late-stage trials)
Bortezomib	Phase 3 (in late-stage trials)
Calcium Carbonate	Phase 3 (in late-stage trials)
Carboplatin	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Clarithromycin	Phase 3 (in late-stage trials)
Copanlisib	Phase 3 (in late-stage trials)
Cyclosporine	Phase 3 (in late-stage trials)
Cytarabine	Phase 3 (in late-stage trials)
Daunorubicin	Phase 3 (in late-stage trials)
Dexamethasone	Phase 3 (in late-stage trials)
Doxorubicin	Phase 3 (in late-stage trials)
Enzastaurin	Phase 3 (in late-stage trials)
Ergocalciferol	Phase 3 (in late-stage trials)
Etoposide	Phase 3 (in late-stage trials)
Filgrastim	Phase 3 (in late-stage trials)
Fludarabine	Phase 3 (in late-stage trials)
Gemcitabine	Phase 3 (in late-stage trials)
Histamine	Phase 3 (in late-stage trials)
Ibritumomab Tiuxetan	Phase 3 (in late-stage trials)
Ibrutinib	Phase 3 (in late-stage trials)
Idarubicin	Phase 3 (in late-stage trials)
Ifosfamide	Phase 3 (in late-stage trials)
Inotuzumab Ozogamicin	Phase 3 (in late-stage trials)
Lenalidomide	Phase 3 (in late-stage trials)
Lisocabtagene Maraleucel	Phase 3 (in late-stage trials)
Metronidazole	Phase 3 (in late-stage trials)
Mosunetuzumab	Phase 3 (in late-stage trials)
Mycophenolate Mofetil	Phase 3 (in late-stage trials)
Obinutuzumab	Phase 3 (in late-stage trials)
Ofatumumab	Phase 3 (in late-stage trials)
Oxaliplatin	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Pixantrone	Phase 3 (in late-stage trials)
Polatuzumab Vedotin	Phase 3 (in late-stage trials)
Prednisolone	Phase 3 (in late-stage trials)
Prednisone	Phase 3 (in late-stage trials)
Sargramostim	Phase 3 (in late-stage trials)
Sirolimus	Phase 3 (in late-stage trials)
TOSITUMOMAB 131I	Phase 3 (in late-stage trials)
Tacrolimus Anhydrous	Phase 3 (in late-stage trials)
Tisagenlecleucel	Phase 3 (in late-stage trials)
Tocilizumab	Phase 3 (in late-stage trials)
Tositumomab	Phase 3 (in late-stage trials)
Vincristine	Phase 3 (in late-stage trials)
Vinorelbine	Phase 3 (in late-stage trials)
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN	Phase 3 (in late-stage trials)
Zanubrutinib	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): 1018 ISS, ANTINEOPLASTON A10, Acalabrutinib, Acetaminophen, Aldesleukin, Amifostine, Ascorbic Acid, Atezolizumab, Atorvastatin, Belinostat, Bevacizumab, Blinatumomab, Busulfan, CPI 613, Clofarabine, Crisantaspase, Denileukin Diftitox, Diphenhydramine, Durvalumab, Duvelisib, Entospletinib, Epcoritamab, Epirubicin, Epratuzumab, Etoposide Phosphate, Fludarabine Phosphate, Gallium Nitrate, Golcadomide, Irinotecan, Lamivudine, Lomustine, Loncastuximab Tesirine, Melphalan, Methylprednisolone, Mitoxantrone, Motexafin Gadolinium, Motixafortide, Nivolumab, Odronextamab, Ondansetron, Panobinostat, Pegargiminase, Pegfilgrastim, Pembrolizumab, Potassium Iodide, Romiplostim, Tafasitamab, Temozolomide, Temsirolimus, Tetracycline, Thalidomide, Tislelizumab, Topotecan, Treosulfan, Tucidinostat, Umbralisib, Venetoclax, Vorinostat.

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 4 · Undrugged: 4

Druggability breadth: 6 of 8 evidence-associated genes (75%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
EZH2	TAZEMETOSTAT
BRAF	VEMURAFENIB
TP53	NITROFURANTOIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TP53	196	4
BRAF	48	4
EZH2	6	4
RAD54L	1	2
CASP10	0	0
LRRC41	0	0
RAD54B	0	0
B2M	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
TAZEMETOSTAT	4	EZH2
VEMURAFENIB	4	BRAF
PONATINIB	4	BRAF
FEDRATINIB	4	BRAF
SORAFENIB	4	BRAF
DASATINIB ANHYDROUS	4	BRAF
RUXOLITINIB	4	BRAF
INFIGRATINIB PHOSPHATE	4	BRAF
INFIGRATINIB	4	BRAF
REGORAFENIB	4	BRAF
DABRAFENIB	4	BRAF
COBIMETINIB	4	BRAF
NILOTINIB	4	BRAF
ABEMACICLIB	4	BRAF
ENCORAFENIB	4	BRAF
TOVORAFENIB	4	BRAF
PAZOPANIB	4	BRAF
DASATINIB	4	BRAF
ERLOTINIB	4	BRAF
GEFITINIB	4	BRAF
IMATINIB	4	BRAF
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 5.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BRAF	1,442	Binding:1400, Functional:37, ADMET:5
TP53	869	Binding:775, ADMET:83, Functional:10, Toxicity:1
EZH2	839	Binding:833, Functional:6
CASP10	22	Binding:21, Functional:1
B2M	5	Binding:5
RAD54L	3	Functional:2, Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
EZH2	2.1.1.356	[histone H3]-lysine27 N-trimethyltransferase
BRAF	2.7.10.2, 2.7.11.1	non-specific protein-tyrosine kinase, non-specific serine/threonine protein kinase
CASP10	3.4.22.63	caspase-10
RAD54B	3.6.4.B9
RAD54L	3.6.4.B9

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
EZH2	839
BRAF	1,442
TP53	869

Pharmacogenomics

Cohort genes with a PharmGKB record: 8; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
TAZEMETOSTAT	4	EZH2
VEMURAFENIB	4	BRAF
PONATINIB	4	BRAF
FEDRATINIB	4	BRAF
SORAFENIB	4	BRAF
DASATINIB ANHYDROUS	4	BRAF
RUXOLITINIB	4	BRAF
INFIGRATINIB PHOSPHATE	4	BRAF
INFIGRATINIB	4	BRAF
REGORAFENIB	4	BRAF
DABRAFENIB	4	BRAF
COBIMETINIB	4	BRAF
NILOTINIB	4	BRAF
ABEMACICLIB	4	BRAF
ENCORAFENIB	4	BRAF
TOVORAFENIB	4	BRAF
PAZOPANIB	4	BRAF
DASATINIB	4	BRAF
ERLOTINIB	4	BRAF
GEFITINIB	4	BRAF
IMATINIB	4	BRAF
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	EZH2, BRAF, TP53
B	Phased (≥1) drug, not yet approved	1	RAD54L
C	Druggable family + PDB, no drug	2	RAD54B, B2M
D	Druggable family + AlphaFold only, no drug	1	CASP10
E	Difficult family or no structure, no drug	1	LRRC41

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
CASP10	22	—
LRRC41	0	—
RAD54B	0	—
B2M	5	—

Clinical trials & evidence

Clinical trials

Clinical trials: 1,051.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	304
PHASE1	304
Not specified	179
PHASE1/PHASE2	162
PHASE3	53
EARLY_PHASE1	26
PHASE4	18
PHASE2/PHASE3	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06665737	PHASE4	NOT_YET_RECRUITING	Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin’s Lymphoma Patients
NCT06876649	PHASE4	RECRUITING	A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876662	PHASE4	RECRUITING	A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT07016165	PHASE4	RECRUITING	Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT00090038	PHASE4	COMPLETED	Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin’s Lymphoma
NCT00162955	PHASE4	COMPLETED	Prevention of CHOP-induced Chronic Cardiotoxicity
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00352703	PHASE4	COMPLETED	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00430352	PHASE4	COMPLETED	MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin’s Lymphoma.
NCT00797810	PHASE4	UNKNOWN	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin’s Lymphoma in Adults
NCT00808171	PHASE4	COMPLETED	Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture
NCT00926757	PHASE4	COMPLETED	Prophylactic Use of Entecavir for Non-Hodgkin’s Lymphoma Patients With Resolved Hepatitis B
NCT00969462	PHASE4	COMPLETED	Doxorubicin Pharmacokinetics and Response in Non Hodgkin’s Lymphoma
NCT01124526	PHASE4	COMPLETED	Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
NCT01164475	PHASE4	COMPLETED	Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin’s Lymphoma (NHL) Weighing Less Than 70 Kilograms
NCT01180049	PHASE4	COMPLETED	Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
NCT02782845	PHASE4	COMPLETED	An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin’s Lymphoma (NHL)
NCT05191225	PHASE4	UNKNOWN	Ultrafast Truxima Infusion in Non-Hodgkin’s Lymphoma: Txagorapid Study
NCT00877214	PHASE3	ACTIVE_NOT_RECRUITING	Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
NCT03844048	PHASE3	ACTIVE_NOT_RECRUITING	An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT04459416	PHASE3	ACTIVE_NOT_RECRUITING	Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
NCT05171647	PHASE3	ACTIVE_NOT_RECRUITING	A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
NCT05645107	PHASE3	RECRUITING	A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT06520163	PHASE3	RECRUITING	Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
NCT07188558	PHASE3	RECRUITING	A Study to Investigate Ronde-cel Versus Investigator’s Choice CD19 CAR T-Cell Therapy
NCT07202052	PHASE2/PHASE3	RECRUITING	Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
NCT07582432	PHASE3	RECRUITING	A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
NCT00039910	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00057343	PHASE3	TERMINATED	Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin’s Lymphoma
NCT00078598	PHASE3	UNKNOWN	A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin’s Lymphoma
NCT00091676	PHASE3	UNKNOWN	Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma
NCT00129090	PHASE3	COMPLETED	Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin’s Lymphoma
NCT00133302	PHASE3	TERMINATED	Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin’s Lymphoma (JCOG9809)
NCT00139841	PHASE3	COMPLETED	Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin’s Lymphoma (NHL) Who Are Refractory to Rituximab
NCT00145652	PHASE3	COMPLETED	Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
NCT00152139	PHASE3	COMPLETED	Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00269113	PHASE3	COMPLETED	A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin’s Lymphoma
NCT00312845	PHASE3	COMPLETED	Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma
NCT00332202	PHASE3	COMPLETED	PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
NCT00352846	PHASE3	COMPLETED	Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RITUXIMAB	4	129
BENDAMUSTINE	4	26
PLERIXAFOR	4	24
2-MERCAPTOETHANESULFONIC ACID	4	12
OBINUTUZUMAB	4	8
CLOFARABINE	4	7
DOXORUBICIN	4	7
MITOXANTRONE	4	7
PEGFILGRASTIM	4	7
POLATUZUMAB VEDOTIN	4	7
UBLITUXIMAB	4	6
VINCRISTINE	4	6
AXICABTAGENE CILOLEUCEL	4	5
BRENTUXIMAB VEDOTIN	4	5
OFATUMUMAB	4	5
BELINOSTAT	4	4
BORTEZOMIB D-MANNITOL	4	4
FLUDARABINE PHOSPHATE	4	4
PALIFERMIN	4	4
PIRTOBRUTINIB	4	4
ROMIDEPSIN	4	4
TEMSIROLIMUS	4	4
MOSUNETUZUMAB	4	3
VENETOCLAX	4	3
ALEMTUZUMAB	4	2
DIPHENHYDRAMINE	4	2
ETOPOSIDE PHOSPHATE	4	2
IBRUTINIB	4	2
MOXETUMOMAB PASUDOTOX	4	2
PANOBINOSTAT	4	2

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 2 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
EZH2 Y646F	Tazemetostat	Sensitivity/Response	CIViC D	EID11000 +1